Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy

The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRAS(G12C)). Though this approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Issahaku, Abdul Rashid, Mukelabai, Namutula, Agoni, Clement, Rudrapal, Mithun, Aldosari, Sahar M., Almalki, Sami G., Khan, Johra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588042/
https://www.ncbi.nlm.nih.gov/pubmed/36273239
http://dx.doi.org/10.1038/s41598-022-22668-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588042/
https://www.ncbi.nlm.nih.gov/pubmed/36273239
http://dx.doi.org/10.1038/s41598-022-22668-1

Ejemplares similares